DengiAll:
India’s efforts to develop a safe and effective dengue vaccine have taken a significant leap forward, with its first indigenous tetravalent dengue vaccine, DengiAll, reaching 50% enrolment in Phase 3 clinical trials. It is developed by Panacea Biotec under a licensing agreement with the US National Institutes of Health (NIH), targeting all four dengue virus subtypes. The vaccine has shown a balanced and robust immune response in Phase I and II trials, with no major safety concerns reported. The vaccine is significant as dengue currently has no specific treatment for everyone, and severe cases can lead to life-threatening complications like internal bleeding and shock. It is a mosquito-borne viral disease caused by the dengue virus (genus Flavivirus), primarily transmitted by the female Aedes aegypti mosquito. This mosquito also spreads chikungunya, yellow fever, and Zika. There are four distinct but related dengue serotypes: DEN-1, DEN-2, DEN-3, and DEN-4. Symptoms: High fever, severe headache, eye pain, muscle and joint pain, rash, and fatigue. Diagnosis and Treatment: Diagnosis is done via blood test. There is no specific antiviral treatment; care is supportive.